92 related articles for article (PubMed ID: 18955045)
1. Regulation of CRABP-II expression by MycN in Wilms tumor.
Gupta A; Kessler P; Rawwas J; Williams BR
Exp Cell Res; 2008 Dec; 314(20):3663-8. PubMed ID: 18955045
[TBL] [Abstract][Full Text] [Related]
2. Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma.
Gupta A; Williams BR; Hanash SM; Rawwas J
Cancer Res; 2006 Aug; 66(16):8100-8. PubMed ID: 16912187
[TBL] [Abstract][Full Text] [Related]
3. p53 is a direct transcriptional target of MYCN in neuroblastoma.
Chen L; Iraci N; Gherardi S; Gamble LD; Wood KM; Perini G; Lunec J; Tweddle DA
Cancer Res; 2010 Feb; 70(4):1377-88. PubMed ID: 20145147
[TBL] [Abstract][Full Text] [Related]
4. Array comparative genomic hybridization reveals unbalanced gain of the MYCN region in Wilms tumors.
Schaub R; Burger A; Bausch D; Niggli FK; Schäfer BW; Betts DR
Cancer Genet Cytogenet; 2007 Jan; 172(1):61-5. PubMed ID: 17175381
[TBL] [Abstract][Full Text] [Related]
5. MYCN is recruited to the RASSF1A promoter but is not critical for DNA hypermethylation in neuroblastoma.
Charlet J; Szemes M; Malik KT; Brown KW
Mol Carcinog; 2014 May; 53(5):413-20. PubMed ID: 23280764
[TBL] [Abstract][Full Text] [Related]
6. CRABP-II methylation: a critical determinant of retinoic acid resistance of medulloblastoma cells.
Fu YS; Wang Q; Ma JX; Yang XH; Wu ML; Zhang KL; Kong QY; Chen XY; Sun Y; Chen NN; Shu XH; Li H; Liu J
Mol Oncol; 2012 Feb; 6(1):48-61. PubMed ID: 22153617
[TBL] [Abstract][Full Text] [Related]
7. Expression and functional influence of cellular retinoic acid-binding protein II in renal cell carcinoma.
Goelden U; Pfoertner S; Hansen W; Toepfer T; von Knobloch R; Hofmann R; Buer J; Schrader AJ
Urol Int; 2005; 75(3):269-76. PubMed ID: 16215318
[TBL] [Abstract][Full Text] [Related]
8. Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation.
Koppen A; Ait-Aissa R; Hopman S; Koster J; Haneveld F; Versteeg R; Valentijn LJ
Cancer Lett; 2007 Oct; 256(2):218-28. PubMed ID: 17643814
[TBL] [Abstract][Full Text] [Related]
9. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
10. Hypermethylation-mediated regulation of CD44 gene expression in human neuroblastoma.
Yan P; Mühlethaler A; Bourloud KB; Beck MN; Gross N
Genes Chromosomes Cancer; 2003 Feb; 36(2):129-38. PubMed ID: 12508241
[TBL] [Abstract][Full Text] [Related]
11. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
[TBL] [Abstract][Full Text] [Related]
12. Retinoic acid induced downregulation of MYCN is not mediated through changes in Sp1/Sp3.
Kanemaru KK; Tuthill MC; Takeuchi KK; Sidell N; Wada RK
Pediatr Blood Cancer; 2008 Apr; 50(4):806-11. PubMed ID: 17554788
[TBL] [Abstract][Full Text] [Related]
13. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma.
Alaminos M; Davalos V; Cheung NK; Gerald WL; Esteller M
J Natl Cancer Inst; 2004 Aug; 96(16):1208-19. PubMed ID: 15316056
[TBL] [Abstract][Full Text] [Related]
14. Demethylation in the 5'-flanking region of mouse cellular retinoic acid binding protein-I gene is associated with its high level of expression in mouse embryos and facilitates its induction by retinoic acid in P19 embryonal carcinoma cells.
Wei LN; Lee CH
Dev Dyn; 1994 Sep; 201(1):1-10. PubMed ID: 7528580
[TBL] [Abstract][Full Text] [Related]
15. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.
Williams RD; Al-Saadi R; Chagtai T; Popov S; Messahel B; Sebire N; Gessler M; Wegert J; Graf N; Leuschner I; Hubank M; Jones C; Vujanic G; Pritchard-Jones K; ;
Clin Cancer Res; 2010 Apr; 16(7):2036-45. PubMed ID: 20332316
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.
Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C
Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372
[TBL] [Abstract][Full Text] [Related]
17. Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor.
Williams RD; Al-Saadi R; Natrajan R; Mackay A; Chagtai T; Little S; Hing SN; Fenwick K; Ashworth A; Grundy P; Anderson JR; Dome JS; Perlman EJ; Jones C; Pritchard-Jones K
Genes Chromosomes Cancer; 2011 Dec; 50(12):982-95. PubMed ID: 21882282
[TBL] [Abstract][Full Text] [Related]
18. Gain of MYCN region in a Wilms tumor-derived xenotransplanted cell line.
Noguera R; Villamón E; Berbegall A; Machado I; Giner F; Tadeo I; Navarro S; Llombart-Bosch A
Diagn Mol Pathol; 2010 Mar; 19(1):33-9. PubMed ID: 20186010
[TBL] [Abstract][Full Text] [Related]
19. Involvement of germline DDX1-MYCN duplication in inherited nephroblastoma.
Fievet A; Belaud-Rotureau MA; Dugay F; Abadie C; Henry C; Taque S; Andrieux J; Guyetant S; Robert M; Dubourg C; Edan C; Rioux-Leclercq N; Odent S; Jaillard S
Eur J Med Genet; 2013 Dec; 56(12):643-7. PubMed ID: 24161495
[TBL] [Abstract][Full Text] [Related]
20. Multiple mechanisms of MYCN dysregulation in Wilms tumour.
Williams RD; Chagtai T; Alcaide-German M; Apps J; Wegert J; Popov S; Vujanic G; van Tinteren H; van den Heuvel-Eibrink MM; Kool M; de Kraker J; Gisselsson D; Graf N; Gessler M; Pritchard-Jones K
Oncotarget; 2015 Mar; 6(9):7232-43. PubMed ID: 25749049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
